-
Potential targeted therapy found for newly identified leukemia subtype with poor outcome
The MEF2D-rearranged subtype of acute lymphoblastic leukemia (ALL) is linked to poor outcomes. Now a possible targeted therapy has been identified.
-
Mobile health app to help sickle cell patients
National Institutes of Health funding will help physicians and researchers improve hydroxyurea treatment management for sickle cell patients in Memphis.
-
Researchers uncover genetic hallmarks of ALL subtype
Research from the Pediatric Cancer Genome Project identifies the mechanism of action for two transcription factors underlying a type of B-precursor acute lymphoblastic leukemia.
-
Researchers reveal genomic landscape of CBF-AML
Research from the Pediatric Cancer Genome Project identifies genomic landscape that contributes to the diversity of core-binding factor acute myeloid leukemia.
-
Chemo drug impairs multitasking for some survivors
Higher blood levels of methotrexate during treatment of childhood leukemia have been linked to diminished executive function in long-term survivors.
-
Patient safety benefits when hospitals provide feedback
To improve patient safety, hospital leaders should provide feedback that demonstrates to staff the value of reporting safety events and errors.
From Promise, Winter 2017